Type of Mesothelioma:
Mesothelioma Contrast Pharmacokinetics: A Feasibility Trial of the Use of Pharmacokinetic Analysis in Small-Volume Pleural Malignancy
Radiology. Cardiothoracic Imaging 2026 February [Link] Gordon W Cowell, Selina Tsim, David B Stobo, Colin Noble, Catherine A Humphreys, Rosie Woodward, John E Foster, Craig Dick, Kevin G Blyth Abstract Purpose To assess the feasibility of dynamic contrast-enhanced (DCE) MRI-derived pharmacokinetic factor acquisition and performance in patients with suspected small-volume pleural malignancy. Materials and Methods…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 January 9 [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition…
Read MoreThe usefulness of full-thickness biopsy during semi-rigid pleuroscopy for differentiating between malignant pleural mesothelioma and non-specific pleurisy
BMC Pulmonary Medicine 2025 December 10 [Link] Takahiro Ueda, Toshiyuki Nakai, Sayaka Tanaka, Hiroaki Nagamine, Atsushi Miyamoto, Misako Nishimura, Yoshiya Matsumoto, Kanako Sato, Kazuhiro Yamada, Tetsuya Watanabe, Kazuhisa Asai, Yuji Matsumoto, Yu Mikami, Tomoya Kawaguchi Abstract Background: Malignant pleural mesothelioma is a rare disease with a poor prognosis; distinguishing it from non-specific pleurisy is essential…
Read MoreTargeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin
Cancer Research Communications 2025 December 10 [Link] Pınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, Kirstine Sandal Nørregaard, Henrik Gårdsvoll, Jingli Zhang, Henrik Jessen Jürgensen, Michaela Hansen Blomquist, Alba Martinez Perlado, Oliver Krigslund, Eric Santoni-Rugiu, Lars Henning Engelholm, Raffit Hassan, Niels Behrendt Abstract uPARAP is a collagen-internalizing receptor with emerging relevance as a therapeutic target.…
Read MoreMultiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype
Journal of Thoracic Oncology 2025 November 28 [Link] David T Severson, Samuel Freyaldenhoven, Benjamin Wadowski, Yin P Hung, Travis Hughes, Beow Y Yeap, William G Richards, Sanna Laaksonen, Lucian Chirieac, Matthew B Couger, Roderick V Jensen, Ahmed A Sadek, Ilkka Ilonen, Kimberly Vermilya, Simona Innocenti, Stephanie L Korle, Julianne S Barlow, Jamie Anderson, Jason Meyerovitz,…
Read MoreCirculating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma
Lung Cancer 2025 December [Link] Evgeniya Sharova, Paola Del Bianco, Loredana Urso, Micol Silic-Benussi, Daniela Scattolin, Donna M D’Agostino, Giulia Pasello, Vincenzo Ciminale Abstract Introduction: Pleural mesothelioma (PM) is an aggressive neoplasm associated with asbestos exposure. Clinical management of PM poses major challenges due to the lack of reliable markers for early diagnosis and prognostic…
Read MorePembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
The Lancet. Oncology 2025 December [Link] Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer Abstract Background: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in…
Read MoreA novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing
Scientific Reports 2025 November 21 [Link] Yang Liu, Yang Yang, Songlin An, Hua Wan, Minghao Zhang, Ruihong Yin, Weiting Zhao, Li Huang, Yunshan Zhao, Chenggang Li Abstract Malignant mesothelioma (MM) is a rare, aggressive cancer with poor outcomes due to its heterogeneity and therapy resistance. Patient-derived organoids (PDOs) have emerged as a promising tool for…
Read MoreHyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases
Oncology 2025 November 20 [Link] Yu-An Zheng, Ke-Cheng Chen, Pei-Ming Huang, Mong-Wei Lin, Shuenn-Wen Kuo, Jang-Ming Lee Abstract Introduction: Hyperthermic intrathoracic chemotherapy (HITHOC) is an intraoperative treatment that involves the perfusion of heated chemotherapy agents within the thoracic cavity. Photodynamic therapy (PDT) utilizes systemically administered photosensitizing agents and targeted light exposure to eliminate residual cancer…
Read MoreUnraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Management
Cureus 2025 October 15 [Link] Othmane Zouiten, Latifa Azarou, Hasnaa Hadiri, Hanane Rais, Rhizlane Belbaraka Abstract Peritoneal mesothelioma is a rare and aggressive tumor, and its management remains poorly standardized in the literature. This case highlights the diagnostic and therapeutic challenges through a 56-year-old woman with no significant medical history or known asbestos exposure, who…
Read More
Skip to content